Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
- Registry ID
- EUCTR2009-011793-14
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Karolinska Institute/Hospital
- Start date
- 2009-09-08
- Completion date
- 2014-11-11
- Last update
- 2026-08-16
Conditions
- Advanced pancreatic cancer
Summary
Phase I: To determine the MTD (Maximum Tolerated Dose) and safety of the regimen lenalidomide and gemcitabine as first-line treatment in subjects with pancreatic cancer. Phase II: To evaluate the immunomodulatory effects of the regimen lenalidomide and gemcitabine as first-line treatment in subjects with pancreatic cancer.
Locations
View on source registry